239: Rheum for Improvement: axial SpA and PsA

Sunday, November 13, 2022

6:30 PM – 8:30 PM Eastern Time

Location: Marriott, Grand Ballroom E

All of the relevant financial relationships listed for faculty have been mitigated.

Industry Presenter(s)

Atul Deodhar, MD

Professor of Medicine, Division of Arthritis and Rheumatic Diseases, School of Medicine
Oregon Health & Science University
Portland, OR, United States

Disclosure information not submitted.
FM

Fardina Malik, MD

Assistant Professor
Department of Medicine at NYU Grossman School of Medicine
New York, New York, United States

Disclosure information not submitted.
M. Elaine Husni, MD, MPH

Cleveland Clinic
Gates Mills, OH, United States

Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)

Join our expert panel as they discuss the benefits of aiming for higher treatment targets for patients with axial SpA and PsA, with a focus on how treatment strategies and the current treatment landscape and can help achieve these goals. The agenda includes a panel discussion, where our experts will evaluate the practicalities of measuring stringent treatment targets in the clinic, and you can ask your questions of the panel. We look forward to seeing you there.

Developed and offered by UCB